Giblo et al, 1000+ pop-based cohort RA: Cumulative incidence of depression = Increase in cumulative incidence of anxiety 2005–14 vs. earlier decades Despite improvements in RA ttmts. Maybe time we address these separately? https://t.co/Z3FUgSETKW Abs#0889 #ACR22 @Rheumnow https://t.co/Rn2ru80021

• Incidence of Depression and Anxiety in Rheumatoid Arthritis Patients over Three…

Kang @karen_kc123 et al ≥ 20 pack-years cigarette smoking associated with higher risk of incident PMR in women (HR 1.46). Every 10 pack-years associated 9% increase in risk @RheumNow #ACR22 Abstr#0698 https://t.co/t51fKFs7iJ https://t.co/IS9XC9DXl8

• Cohort Study of Cigarette Smoking and the Risk of Developing Polymyalgia Rheuma…

Maguire @Sineadm15 @rheum_covid (and me!) obstetric outcomes in RMD and COVID-19. Unvaccinated higher freq pre-term birth. Regardless of vaccine status, the women themselves did well, rarely needing pharmacotherapy @RheumNow #ACR22 Abstr#0950 #ACRbest https://t.co/GLMAAvbC4a https://t.co/kpXZbRSoMo

• Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context …

DIPSA: RCT in PsA pts w/ BMI > 25 Mediterranean diet vs. DASH-low caloric diet vs. SoC BL: 72% obese, 42% dyslipidemia, 38% HBP, MetS 47% Looking forward to seeing the results of this dietary intervention, MetS is high in PsA! https://t.co/29Aq0TLANO Abs#1007 #ACR22 @Rheumnow https://t.co/MoVYnQV6xR

• Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Ps…

Ab0411 #ACR22 Bimekizumab in AS P3 24 wk PBO control study BE-MOBILE 2 221 BKZ, 111 PBO Wk 16 ASAS40: BKZ 45%, 22% PBO p<0.001 Efficacy in both TNF naive and TNF failure pts Wk 24: 1/2 pts has ASDAS<2.1 Nasopharyngitis (6%), diarrhea (4%), h/a (3.6%) 👅candidiasis (3%) @Rheumnow https://t.co/R1ieW0FB6m

Mathew et al. Combination biologics from MarketScan. Combination less likely to have ER visit in 180 days 17% vs 23% @RheumNow #ACR22 Abstr#0768 https://t.co/Y880qDXMow https://t.co/gOH2Zlt6UV

• Reevaluating Clinical Outcomes of Patients on Combination Biologics - ACR Meeti…

CASIPSA study: retro CT SIJ analysis 48 PsA & age/sex matched ctrls. JSN, erosion, sclerosis in 1/3 pts w/ peripheral & 1/3 pts w/ axial disease. PsA > erosions, no diff in other parameters: lack of power or true absence of diff? https://t.co/CR0LymrinT Abs#1012 #ACR22 @Rheumnow https://t.co/akYYqbIFNx

• Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Art…

Wang @zach_wallace_md et al. Machine learning can accurately classify clinical note sections as reflecting a diagnosis of AAV. As a machine learning sceptic, data like this helps (slowly) convert me. @RheumNow #ACR22 Abstr#0700 https://t.co/qbq9j9XzXG https://t.co/8iNJElI2vJ

• Accurate Identification of ANCA-Associated Vasculitis Cases from Clinical Notes…

I typically do not use mepolizumab for "vasculitic" EGPA --> recent ACR/VF guidelines agreed Interesting study @TerrierBen suggests benefit regardless of ANCA, BVAS, VDI Have others been using in this context or seen similar? #ACR22 @RheumNow #ACRBest #1075 https://t.co/C6isdSn2eI

Are we really treating Psoriatic disease if we only address active disease domains and T2T? #ACR22 https://t.co/D3F5EzLfeP https://t.co/TO3GyZA6Lb

• https://bit.ly/3E4Q5SJ

#ACR22 Abstr#1654 Press Release #lupus. A cohort study using case-crossover design showed that HCQ dose =<5mg/kg actual body weight OR <400mg/day were associated with increased risk of severe #SLE flare requiring hospitalisation. Need to review Guidelines on HCQ dose @RheumNow https://t.co/5mMh7g6wcA

Toxic granules in blood vessels may damage vasculature and cause fibrosis around vessels. ‘Occult vascular disease occurs in #scleroderma, don’t forget about it’ says Wigley at Hench Memorial Lecture #ACR22 ⁦@RheumNow⁩ ⁦@ACRheum⁩ insights by a humble #SSc leader 🙏🏻 https://t.co/M82p6DwZ6Q

AURORA 2 data VOC-treated pts w/ pure and mixed Class V lupus nephritis saw reductions in UPCR that occurred faster than in those treated with MMF and low-dose steroids alone. Abs 0355 #ACR22 @RheumNow https://t.co/eHVLDCcti8 https://t.co/jbuiOSqqsa

• Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results …

Targeting MRI remission in RA, specifically targeting osteitis, did not confer benefit over clinical T2T over 2 years. Maybe our clinical examination is not so bad afterall @steverheum_hall @RheumNow ABST0890 #ACR22 https://t.co/8nUjWQONyk https://t.co/xGzZNLiJ7U

• Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Diseas…

Meng MA of risk of tapering MTX from combo with bDMARD/tsDMARD in RA in remission. RR 0.90 (95% CI 0.84, 0.97) for maintaining remission over maximum 18 months. Authors conclude little risk to stopping - I disagree 10% is >0. @RheumNow #ACR22 Abstr#0916 https://t.co/9lJXdeVmpg https://t.co/CEV29Mc8uW

• Should RA Patients with Controlled Disease Taper Methotrexate from Targeted The…